NCT06241118: An ongoing trial by Sanofi
This trial is ongoing. It must report results 2 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06241118 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 29, 2024 |
| Completion date | Sept. 30, 2027 |
| Required reporting date | Sept. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |